Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a ...

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

Cancer is becoming a global crisis shaped less by biology than by inequality, risk exposure, and access to care.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. On the regional level, as the Human Development Index ...